HUP0105489A2 - Kit fehérjék ittrium-90-nel való jelölésére - Google Patents

Kit fehérjék ittrium-90-nel való jelölésére

Info

Publication number
HUP0105489A2
HUP0105489A2 HU0105489A HUP0105489A HUP0105489A2 HU P0105489 A2 HUP0105489 A2 HU P0105489A2 HU 0105489 A HU0105489 A HU 0105489A HU P0105489 A HUP0105489 A HU P0105489A HU P0105489 A2 HUP0105489 A2 HU P0105489A2
Authority
HU
Hungary
Prior art keywords
protein
yttrium
kit
chelating agent
peptide
Prior art date
Application number
HU0105489A
Other languages
English (en)
Inventor
Paul Chinn
Original Assignee
Idec Pharmaceuticals Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idec Pharmaceuticals Corporation filed Critical Idec Pharmaceuticals Corporation
Publication of HUP0105489A2 publication Critical patent/HUP0105489A2/hu
Publication of HUP0105489A3 publication Critical patent/HUP0105489A3/hu
Publication of HU227986B1 publication Critical patent/HU227986B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/534—Production of labelled immunochemicals with radioactive label
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

A találmány kelátképzővel konjugált fehérje vagy peptid terápiásradioizotóppal való jelzésére alkalmas eljárásra vonatkozik, amelyabból áll, hogy (i) a kelátképzővel konjugált fehérjét vagy peptidet aradioizotópot vagy annak sóját tartalmazó oldattal elegyítik, és (ii)az elegyet megfelelő ideig, kedvező körülmények között inkubálják, úgyhogy egy radiojelzett fehérjét vagy peptidet kapnak, amely megfelelőtisztaságú, fajlagos aktivitású és kötődési specifitású, és így aradiojelzett antitest a betegnek közvetlenül, további tisztítás nélkülbeadható. Az eljáráshoz alkalmazható kit is a találmány tárgyátképezi. Ó
HU0105489A 1999-03-01 2000-02-29 Method for production of direct applicable radioactively labelled proteins or polypeptides HU227986B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25933899A 1999-03-01 1999-03-01
PCT/US2000/005078 WO2000052031A2 (en) 1999-03-01 2000-02-29 Kit for radiolabeling proteins with yttrium-90

Publications (3)

Publication Number Publication Date
HUP0105489A2 true HUP0105489A2 (hu) 2002-05-29
HUP0105489A3 HUP0105489A3 (en) 2005-10-28
HU227986B1 HU227986B1 (en) 2012-07-30

Family

ID=22984528

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0105489A HU227986B1 (en) 1999-03-01 2000-02-29 Method for production of direct applicable radioactively labelled proteins or polypeptides

Country Status (36)

Country Link
US (3) US6994840B1 (hu)
EP (2) EP2011520A1 (hu)
JP (1) JP4558947B2 (hu)
KR (1) KR100734023B1 (hu)
CN (1) CN1251767C (hu)
AT (1) ATE428446T1 (hu)
AU (1) AU780311B2 (hu)
BG (1) BG65568B1 (hu)
BR (1) BR0008635A (hu)
CA (1) CA2362908C (hu)
CY (1) CY1109211T1 (hu)
CZ (1) CZ20013127A3 (hu)
DE (2) DE1156835T1 (hu)
DK (1) DK1156835T3 (hu)
EE (1) EE05582B1 (hu)
ES (1) ES2165830T3 (hu)
GR (1) GR20010300078T1 (hu)
HK (1) HK1045656B (hu)
HR (1) HRP20010713A2 (hu)
HU (1) HU227986B1 (hu)
IL (2) IL145112A0 (hu)
ME (1) ME00783B (hu)
MX (1) MXPA01008745A (hu)
MY (1) MY133346A (hu)
NO (1) NO330728B1 (hu)
NZ (1) NZ513667A (hu)
PL (1) PL204239B1 (hu)
PT (1) PT1156835E (hu)
RS (1) RS50342B (hu)
RU (1) RU2221807C2 (hu)
SI (1) SI1156835T1 (hu)
SK (1) SK287650B6 (hu)
TW (1) TWI283178B (hu)
UA (1) UA75036C2 (hu)
WO (1) WO2000052031A2 (hu)
ZA (1) ZA200106945B (hu)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY133346A (en) * 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
US20020102208A1 (en) * 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
DE60143535D1 (de) 2000-10-02 2011-01-05 Novartis Vaccines & Diagnostic Humane antikörper gegen cd40
US6696060B2 (en) * 2001-06-14 2004-02-24 Clearant, Inc. Methods for sterilizing preparations of monoclonal immunoglobulins
US7252799B2 (en) 2001-08-31 2007-08-07 Clearant, Inc. Methods for sterilizing preparations containing albumin
US6783968B2 (en) 2001-09-24 2004-08-31 Clearant, Inc. Methods for sterilizing preparations of glycosidases
US6974563B2 (en) 2002-06-18 2005-12-13 Lynntech, Inc. Ion exchange materials for the separation of 90Y from 90SR
WO2004066933A2 (en) * 2003-01-27 2004-08-12 Biogen Idec Ma Inc. Compositions and methods for treating cancer using igsf9 and liv-1
ES2486845T3 (es) * 2003-04-15 2014-08-19 Algeta Asa Torio-227 para ser usado en radioterapia de enfermedad de partes blandas
ES2346978T3 (es) 2003-11-04 2010-10-22 Novartis Vaccines And Diagnostics, Inc. Uso de anticuerpos monoclonantes anti-cd40 antagonistas para el tratamiento del mieloma multiple.
EP1694360B1 (en) 2003-11-04 2010-08-04 Novartis Vaccines and Diagnostics, Inc. Use of antagonist anti-cd40 antibodies for treatment of autoimmune and inflammatory diseases and organ transplant rejection
WO2005044304A2 (en) 2003-11-04 2005-05-19 Chiron Corporation Use of antagonist anti-cd40 antibodies for treatment of chronic lymphocytic leukemia
EP2236172A1 (en) 2003-11-04 2010-10-06 Novartis Vaccines and Diagnostics, Inc. Combination therapy comprising anti-CD20 and anti-CD40 antibodies for the treatment of B cell-related cancers
EP2301575A1 (en) 2003-11-04 2011-03-30 Novartis Vaccines and Diagnostics, Inc. Methods of therapy for solid tumors expressing the CD40 cell-surface antigen
JP5421590B2 (ja) 2005-05-18 2014-02-19 ノバルティス アーゲー 自己免疫および／または炎症性成分を有する疾患の診断および治療のための方法
EA018301B1 (ru) 2006-04-21 2013-07-30 Новартис Аг Фармацевтические композиции, содержащие антагонистическое моноклональное антитело к cd40, и их применение
GB0700133D0 (en) 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
SG10201608381SA (en) 2008-07-16 2016-11-29 Inst Research In Biomedicine Human cytomegalovirus neutralizing antibodies and use thereof
JP5475774B2 (ja) 2008-07-16 2014-04-16 インスティテュート フォー リサーチ イン バイオメディシン ヒトサイトメガロウイルス中和抗体およびその使用
NZ590890A (en) 2008-07-25 2013-05-31 Inst Research In Biomedicine Neutralizing anti-influenza a virus antibodies and uses thereof
US8871207B2 (en) 2008-07-25 2014-10-28 Humabs, LLC Neutralizing anti-influenza A virus antibodies and uses thereof
CN108610416B (zh) 2008-10-13 2022-01-14 生物医学研究所 登革热病毒中和抗体及其用途
US20110212106A1 (en) 2010-01-20 2011-09-01 Institute For Research In Bioscience Hiv-1 neutralizing antibodies and uses thereof
GB201002508D0 (en) 2010-02-12 2010-03-31 Algeta As Product
WO2011147762A2 (en) * 2010-05-25 2011-12-01 Bayer Pharma Aktiengesellschaft Stabilized radiopharmaceutical composition
KR102498607B1 (ko) * 2010-12-22 2023-02-13 제너럴 일렉트릭 캄파니 방사성표지 ｈｅｒ２ 결합 펩티드
HUE044089T2 (hu) 2011-07-18 2019-09-30 Inst Res Biomedicine Neutralizáló anti-influenza A antitestek és alkalmazásaik
EA030319B1 (ru) 2012-03-20 2018-07-31 Хумабс Биомед Са Антитела, нейтрализующие rsv, mpv и pvm, и их применения
RU2537175C2 (ru) * 2013-03-26 2014-12-27 Российская Федерация, От Имени Которой Выступает Министерство Образования И Науки Российской Федерации Способ получения радиоиммунного препарата для диагностики и терапии онкологических заболеваний
PE20160244A1 (es) 2013-08-13 2016-05-10 Sanofi Sa Anticuerpos contra el inhibidor del activador de plasminogeno tipo 1 (pai-1) y usos de los mismos
SG11201602522VA (en) 2013-10-02 2016-04-28 Medimmune Llc Neutralizing anti-influenza a antibodies and uses thereof
MX2017000595A (es) 2014-07-15 2017-10-12 Medimmune Llc Anticuerpos anti-influenza b neutralizantes y usos de los mismos.
US20170296650A1 (en) 2014-10-08 2017-10-19 Novartis Ag Combination of human cytomegalovirus neutralizing antibodies
WO2016075546A2 (en) 2014-11-14 2016-05-19 Antonio Lanzavecchia Antibodies that neutralize ebola virus and uses thereof
BR112017010298B1 (pt) 2014-11-18 2023-10-31 Humabs Biomed Sa Anticorpos que neutralizam de modo potente vírus da raiva e outros lissavírus, usos dos mesmos, molécula de ácido nucleico, vetor, célula isolada, composição farmacêutica, e kit de partes
IL237525A (en) * 2015-03-03 2017-05-29 Shalom Eli Method for labeling a prostate-specific membrane antigen with a radioactive isotope
GB201504064D0 (en) 2015-03-10 2015-04-22 Accretion Biotechnology Ltd Method and kits for preparing radionuclide complexes
US10442854B2 (en) 2015-06-01 2019-10-15 Medimmune, Llc Neutralizing anti-influenza binding molecules and uses thereof
WO2017059878A1 (en) 2015-10-07 2017-04-13 Humabs Biomed Sa Antibodies that potently neutralize hepatitis b virus and uses thereof
AU2017207330C1 (en) 2016-01-13 2022-06-09 Medimmune, Llc Method of treating influenza A
WO2018010789A1 (en) 2016-07-13 2018-01-18 Humabs Biomed Sa Novel antibodies specifically binding to zika virus epitopes and uses thereof
WO2018193063A2 (en) 2017-04-19 2018-10-25 Institute For Research In Biomedicine Novel malaria vaccines and antibodies binding to plasmodium sporozoites
AU2018265888A1 (en) * 2017-05-12 2019-11-21 Memorial Sloan-Kettering Cancer Center Use of anti-B7H3 antibodies for treating cancer in the central nervous system
WO2019042555A1 (en) 2017-08-31 2019-03-07 Humabs Biomed Sa MULTISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO ZIKA VIRUS EPITOPES AND USES THEREOF
CN109550061A (zh) * 2017-09-26 2019-04-02 南京江原安迪科正电子研究发展有限公司 一种用于放射性核素标记抗体的试剂盒及应用
LT3898668T (lt) 2018-12-19 2023-11-10 Humabs Biomed Sa Antikūnai, neutralizuojantys hepatito b virusą ir jų panaudojimas
MX2022002231A (es) 2019-08-29 2022-03-22 Vir Biotechnology Inc Composiciones de anticuerpos y metodos para tratar la infeccion por el virus de la hepatitis b.
CN111116701A (zh) * 2019-11-14 2020-05-08 浙江普罗亭健康科技有限公司 一种用于蛋白金属标记的中间体及其制备方法、用途
KR20230042023A (ko) 2020-06-24 2023-03-27 비르 바이오테크놀로지, 인코포레이티드 조작된 b형 간염 바이러스 중화 항체 및 이의 용도
US20240092872A1 (en) 2021-01-26 2024-03-21 Vir Biotechnology, Inc. Compositions and methods for treating hepatitis b virus infection
WO2024068944A1 (en) 2022-09-30 2024-04-04 Sanofi Anti-cd28 antibodies
WO2024089609A1 (en) 2022-10-25 2024-05-02 Ablynx N.V. Glycoengineered fc variant polypeptides with enhanced effector function

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3994966A (en) 1972-09-28 1976-11-30 The Board Of Trustees Of The Leland Stanford Junior University Chelating agents
US4043998A (en) 1974-10-09 1977-08-23 The Board Of Trustees Of The Leland Stanford Junior University 1-(P-benzenediazonium)-ethylenediamine tetraacetic acid
US4315851A (en) 1978-12-29 1982-02-16 Kureha Kagaku Kogyo Kabushiki Kaisha Pharmaceutical composition having antitumor activity
US4444744A (en) 1980-03-03 1984-04-24 Goldenberg Milton David Tumor localization and therapy with labeled antibodies to cell surface antigens
US4361544A (en) 1980-03-03 1982-11-30 Goldenberg Milton David Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
US4460559A (en) 1980-03-03 1984-07-17 Goldenberg Milton David Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
US4348376A (en) 1980-03-03 1982-09-07 Goldenberg Milton David Tumor localization and therapy with labeled anti-CEA antibody
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4460561A (en) 1980-03-03 1984-07-17 Goldenberg M David Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
US4622420A (en) 1980-03-18 1986-11-11 The Regents Of The University Of California Chelating agents and method
US4454106A (en) 1982-06-07 1984-06-12 Gansow Otto A Use of metal chelate conjugated monoclonal antibodies
US4472509A (en) 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4707352A (en) 1984-01-30 1987-11-17 Enzo Biochem, Inc. Method of radioactively labeling diagnostic and therapeutic agents containing a chelating group
US4636380A (en) 1984-04-23 1987-01-13 Wong Dennis W Novel physiologic chemical method of labeling protein substances with the radionuclides of indium
US4634586A (en) 1984-05-21 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Reagent and method for radioimaging leukocytes
US4722892A (en) 1984-08-31 1988-02-02 Meares Claude F Monoclonal antibodies against metal chelates
US4824986A (en) 1985-04-26 1989-04-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Metal chelate protein conjugate
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US4926869A (en) 1986-01-16 1990-05-22 The General Hospital Corporation Method for the diagnosis and treatment of inflammation
DK172629B1 (da) 1986-02-14 1999-03-22 Nihon Mediphysics Co Ltd Reaktive højmolekylære forbindelser med mindst én fri aminogruppe, højmolekylære forbindelser kombineret med et fysiologisk
US5099069A (en) 1986-09-05 1992-03-24 Gansow Otto A Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
EP0529645B1 (en) * 1986-09-05 1996-10-23 GANSOW, Otto A. Process for the preparation of backbone polysubstituted chelates
US5246692A (en) 1986-09-05 1993-09-21 The United States Of America As Represented By The Secretary Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5034223A (en) 1986-10-09 1991-07-23 Neorx Corporation Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof
US4921690A (en) 1986-12-29 1990-05-01 City Of Hope Method of enhancing the biodistribution of antibody for localization in lesions
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5130118A (en) 1987-11-06 1992-07-14 Abbott Laboratories Methods and materials for the preparation of metal labelled antibody solutions
AU619218B2 (en) 1987-11-06 1992-01-23 Abbott Laboratories Methods and materials for the preparation of metal labelled antibody solutions
US5217704A (en) 1987-11-06 1993-06-08 Abbott Laboratories Methods and materials for the preparation of metal labelled antibody solutions
US4861579A (en) 1988-03-17 1989-08-29 American Cyanamid Company Suppression of B-lymphocytes in mammals by administration of anti-B-lymphocyte antibodies
US4923985A (en) 1988-05-25 1990-05-08 The United States Of America As Represented By The Department Of Health & Human Services Process for synthesizing macrocyclic chelates
AU630362B2 (en) 1988-05-25 1992-10-29 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Macrocyclic chelates & methods of use thereof
US5059518A (en) 1988-10-20 1991-10-22 Coulter Corporation Stabilized lyophilized mammalian cells and method of making same
CA2010511A1 (en) 1989-03-01 1990-09-01 Roberto L. Ceriani Method of enhancing cancer therapy by administration of unsaturated fatty acids
US5376356A (en) 1989-03-14 1994-12-27 Neorx Corporation Imaging tissue sites of inflammation
US5162115A (en) 1989-05-09 1992-11-10 Pietronigro Dennis D Antineoplastic solution and method for treating neoplasms
US5460785A (en) 1989-08-09 1995-10-24 Rhomed Incorporated Direct labeling of antibodies and other protein with metal ions
US5124471A (en) 1990-03-26 1992-06-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Bifunctional dtpa-type ligand
US5219556A (en) 1990-07-09 1993-06-15 Mallinckrodt Medical, Inc. Stabilized therapeutic radiopharmaceutical complexes
US5009069A (en) 1990-08-24 1991-04-23 Molini Alberto E Method of recovering energy from ocean water
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
JPH06501705A (ja) 1990-11-05 1994-02-24 ブリストル−マイアーズ　スクイブ　カンパニー 抗−腫瘍抗体及び生物学的活性剤の組合せによる相乗治療
US5208008A (en) 1990-11-14 1993-05-04 University Of Pittsburgh Regioselective chemical modification of monoclonal antibodies
CA2075928A1 (en) 1991-01-11 1992-07-12 Roger W. Hackett Method of detecting circulating antibody types using dried or lyophilized cells or cell-like material
US5403573A (en) 1992-04-23 1995-04-04 The Curators Of The University Of Missouri Radiolabeled protein composition and method for radiation synovectomy
US5541287A (en) 1992-06-09 1996-07-30 Neorx Corporation Pretargeting methods and compounds
US5716596A (en) 1992-06-23 1998-02-10 Diatide, Inc. Radioactively labeled somatostatin-derived peptides for imaging and therapeutic uses
US5620675A (en) 1992-06-23 1997-04-15 Diatech, Inc. Radioactive peptides
EP0752248B1 (en) * 1992-11-13 2000-09-27 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5650134A (en) * 1993-01-12 1997-07-22 Novartis Ag (Formerly Sandoz Ltd.) Peptides
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
WO1995019887A1 (fr) 1994-01-24 1995-07-27 Sumitomo Chemical Company, Limited Stratifie, film stratifie et moulage
IL113610A0 (en) 1994-06-03 1995-08-31 Immunomedics Inc A method of radiolabeling a protein, radiolabeled proteins prepared thereby and diagnostic kits containing the same
US5686578A (en) 1994-08-05 1997-11-11 Immunomedics, Inc. Polyspecific immunoconjugates and antibody composites for targeting the multidrug resistant phenotype
US5728369A (en) 1994-10-05 1998-03-17 Immunomedics, Inc. Radioactive phosphorus labeling of proteins for targeted radiotherapy
US5874540A (en) 1994-10-05 1999-02-23 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
US5942210A (en) 1994-11-15 1999-08-24 Cytogen Corporation Methods for lyoprotecting a macromolecule using tricine
US5830431A (en) 1995-06-07 1998-11-03 Mallinckrodt Medical, Inc. Radiolabeled peptide compositions for site-specific targeting
MY133346A (en) * 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
US6300143B1 (en) 1999-03-01 2001-10-09 Idec Pharmaceuticals Corporation Electrochemiluminescent assays for eukaryotic cells
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay

Also Published As

Publication number Publication date
ME00783B (me) 2012-03-20
SK287650B6 (sk) 2011-05-06
NZ513667A (en) 2001-09-28
ES2165830T3 (es) 2009-06-19
CZ20013127A3 (cs) 2002-02-13
SI1156835T1 (sl) 2009-08-31
UA75036C2 (uk) 2006-03-15
KR100734023B1 (ko) 2007-06-29
IL145112A (en) 2007-05-15
ES2165830T1 (es) 2002-04-01
HRP20010713A2 (en) 2002-12-31
BR0008635A (pt) 2001-12-26
RS50342B (sr) 2009-11-10
CN1251767C (zh) 2006-04-19
ZA200106945B (en) 2002-11-22
BG65568B1 (bg) 2008-12-30
NO330728B1 (no) 2011-06-27
JP4558947B2 (ja) 2010-10-06
EE200100461A (et) 2002-10-15
US7618613B2 (en) 2009-11-17
ATE428446T1 (de) 2009-05-15
DK1156835T3 (da) 2009-08-03
DE1156835T1 (de) 2002-05-23
CN1345249A (zh) 2002-04-17
MY133346A (en) 2007-11-30
EP2011520A1 (en) 2009-01-07
MXPA01008745A (es) 2002-04-24
PL204239B1 (pl) 2009-12-31
HU227986B1 (en) 2012-07-30
BG105853A (en) 2002-06-28
KR20020002474A (ko) 2002-01-09
SK12172001A3 (sk) 2002-05-09
US6994840B1 (en) 2006-02-07
CA2362908A1 (en) 2000-09-08
PT1156835E (pt) 2009-07-24
EP1156835A2 (en) 2001-11-28
CY1109211T1 (el) 2014-07-02
WO2000052031A3 (en) 2001-03-01
US20060067884A1 (en) 2006-03-30
HK1045656A1 (en) 2002-12-06
RU2221807C2 (ru) 2004-01-20
AU4004600A (en) 2000-09-21
EP1156835B1 (en) 2009-04-15
IL145112A0 (en) 2002-06-30
PL350551A1 (en) 2002-12-16
TWI283178B (en) 2007-07-01
WO2000052031A2 (en) 2000-09-08
HK1045656B (zh) 2006-09-22
GR20010300078T1 (en) 2002-01-31
AU780311B2 (en) 2005-03-17
EE05582B1 (et) 2012-10-15
US7229620B2 (en) 2007-06-12
DE60042014D1 (de) 2009-05-28
NO20014239D0 (no) 2001-08-31
HUP0105489A3 (en) 2005-10-28
CA2362908C (en) 2012-01-31
US20070297978A1 (en) 2007-12-27
NO20014239L (no) 2001-11-01
YU61701A (sh) 2004-05-12
JP2002538164A (ja) 2002-11-12

Similar Documents

Publication Publication Date Title
HUP0105489A2 (hu) Kit fehérjék ittrium-90-nel való jelölésére
IL113610A0 (en) A method of radiolabeling a protein, radiolabeled proteins prepared thereby and diagnostic kits containing the same
ATE389724T1 (de) Menschliche dnase i hyperaktive varianten
RU2001126396A (ru) Набор для радиоактивного мечения белков иттрием-90
HRP20010714B1 (en) Radiolabeling kit and binding assay
TR199802423T2 (xx) Konsantre antikor terkibi.
HUP0003255A2 (hu) Eljárás faciális fém-trikarbonil vegyületek előállítására és ezek alkalmazása biológiailag aktív szubsztrátok jelzésére
ATE237365T1 (de) Technetium-99-markierte peptide zur visualisierung vom entzuendungen
DE68929043D1 (de) Für androgen-rezeptor-protein kodierende dna
CY1109868T1 (el) Cd81 πρωτεϊνη υποδοχεας ηπατιτιδας c
WO2000015790A3 (en) Leptin induced genes
HUP0004780A2 (hu) Prosztaglandin agonisták felhasználása merevedési rendellenességek vagy impotencia kezelésében
GT199900171A (es) Concentrado oral de sertralina.
ES2032812T3 (es) Vacuna.
DE69529235T2 (de) Menschliche dnase i varianten
HUP0001823A2 (hu) Kémiailag állandó és hőstabil norastemizol készítmények
Westbay Studies on the biochemical basis of oral malodor formation.

Legal Events

Date Code Title Description
HC9A Change of name, address

Owner name: BIOGEN IDEC INC., US

Free format text: FORMER OWNER(S): IDEC PHARMACEUTICALS CORPORATION, US

FH91 Appointment of a representative

Free format text: FORMER REPRESENTATIVE(S): SBGK SZABADALMI UEGYVIVOEI IRODA, HU

Representative=s name: DR. LANG TIVADARNE SZABADALMI UEGYVIVOE, S.B.G, HU

FH92 Termination of representative

Representative=s name: SBGK SZABADALMI UEGYVIVOEI IRODA, HU